Jeffrey A. Meckler, Director at Travere Therapeutics, Inc. (TVTX), sold 8,000 shares at $45.00 ($360K) on 2026-05-04, disclosed to the SEC on 2026-05-06.
Scheduled sale ($360k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| INDP | BUY | 2022-11-22 | $19K | — | Filing → |
| INDP | BUY | 2022-09-12 | $29K | — | Filing → |
| INDP | BUY | 2022-09-08 | $25K | — | Filing → |